نتایج جستجو برای: ژن tp53

تعداد نتایج: 23956  

Journal: :Blood 2013
Annika Dufour Giuseppe Palermo Evelyn Zellmeier Gudrun Mellert Guillemette Duchateau-Nguyen Stephanie Schneider Tobias Benthaus Purvi M Kakadia Karsten Spiekermann Wolfgang Hiddemann Jan Braess Sim Truong Nancy Patten Lin Wu Sabine Lohmann David Dornan Debraj GuhaThakurta Ru-Fang Yeh Galina Salogub Philippe Solal-Celigny Anna Dmoszynska Tadeusz Robak Marco Montillo John Catalano Christian H Geisler Martin Weisser Stefan K Bohlander

In chronic lymphocytic leukemia (CLL) patients, disruptions of the TP53 tumor suppressor pathway by 17p13 deletion (del17p), somatic TP53 mutations, or downregulation of microRNA-34a have been associated with a poor prognosis. So far, the impact of the various TP53 defects has not been evaluated in a large cohort of previously treated and relapsed CLL patients. Here, we present the results of T...

2018
Shigeo Yamaguchi Shin Takahashi Kaoru Mogushi Yuki Izumi Yumi Nozaki Tadashi Nomizu Yoichiro Kakugawa Takanori Ishida Noriaki Ohuchi Chikashi Ishioka Shunsuke Kato

Purpose TP53 signature has a robust predictive performance for prognosis in early-stage breast cancer, but the experiment that reported this relied on public microarray data and fresh-frozen samples. Before TP53 signature can be used in a clinical setting, a simple and low-cost diagnostic system using formalin-fixed paraffin-embedded (FFPE) samples is needed. New treatments based on the biologi...

Journal: :Blood 2012
Frank G Rücker Richard F Schlenk Lars Bullinger Sabine Kayser Veronica Teleanu Helena Kett Marianne Habdank Carla-Maria Kugler Karlheinz Holzmann Verena I Gaidzik Peter Paschka Gerhard Held Marie von Lilienfeld-Toal Michael Lübbert Stefan Fröhling Thorsten Zenz Jürgen Krauter Brigitte Schlegelberger Arnold Ganser Peter Lichter Konstanze Döhner Hartmut Döhner

To assess the frequency of TP53 alterations and their correlation with other genetic changes and outcome in acute myeloid leukemia with complex karyotype (CK-AML), we performed integrative analysis using TP53 mutational screening and array-based genomic profiling in 234 CK-AMLs. TP53 mutations were found in 141 of 234 (60%) and TP53 losses were identified in 94 of 234 (40%) CK-AMLs; in total, 1...

Journal: :International journal of oncology 2011
Birgitte L Adamsen Katherine L Kravik Paula M De Angelis

We studied patterns of DNA damage signaling and cell cycle response to clinically-relevant (bolus) and high doses of 5-fluorouracil (5-FU) in three colorectal cancer cell lines with differing MMR and TP53 status in an attempt to better understand how 5-FU exerts its cytotoxicity. The ATM/CHEK2/ CHEK1 signaling pathway was not activated in response to bolus 5-FU in the MMR-deficient cell lines H...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013
Nataliya Zhukova Vijay Ramaswamy Marc Remke Elke Pfaff David J H Shih Dianna C Martin Pedro Castelo-Branco Berivan Baskin Peter N Ray Eric Bouffet André O von Bueren David T W Jones Paul A Northcott Marcel Kool Dominik Sturm Trevor J Pugh Scott L Pomeroy Yoon-Jae Cho Torsten Pietsch Marco Gessi Stefan Rutkowski Laszlo Bognar Almos Klekner Byung-Kyu Cho Seung-Ki Kim Kyu-Chang Wang Charles G Eberhart Michelle Fevre-Montange Maryam Fouladi Pim J French Max Kros Wieslawa A Grajkowska Nalin Gupta William A Weiss Peter Hauser Nada Jabado Anne Jouvet Shin Jung Toshihiro Kumabe Boleslaw Lach Jeffrey R Leonard Joshua B Rubin Linda M Liau Luca Massimi Ian F Pollack Young Shin Ra Erwin G Van Meir Karel Zitterbart Ulrich Schüller Rebecca M Hill Janet C Lindsey Ed C Schwalbe Simon Bailey David W Ellison Cynthia Hawkins David Malkin Steven C Clifford Andrey Korshunov Stefan Pfister Michael D Taylor Uri Tabori

PURPOSE Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup profiles. PATIENTS AND METHODS We determined subgroup affiliation, TP53 mutation status, and clinical outcome in a discovery cohort of 397 medulloblastomas. We subsequently validated our results on an independent ...

2017
Agnieszka Sliwinska Jacek Kasznicki Marcin Kosmalski Melania Mikołajczyk Aneta Rogalska Karolina Przybylowska Ireneusz Majsterek Jozef Drzewoski

BACKGROUND & OBJECTIVES Tumour protein p53 (TP53) is a stress sensitive transcription factor responsible for the control of cell survival and death to prevent from tumour formation. In vitro and animal studies have indicated that TP53 also responds to metabolic changes and influences metabolic pathways. This study was undertaken to determine the serum level of TP53 and its correlations with cli...

2018
Venkatesh Kancherla Samir Abdullazade Matthias S. Matter Manuela Lanzafame Luca Quagliata Guglielmo Roma Yujin Hoshida Luigi M. Terracciano Charlotte K. Y. Ng Salvatore Piscuoglio

The TP53 gene is the most commonly mutated gene in human cancers and mutations in TP53 have been shown to have either gain-of-function or loss-of-function effects. Using the data generated by The Cancer Genome Atlas, we sought to define the spectrum of TP53 mutations in hepatocellular carcinomas (HCCs) and their association with clinicopathologic features, and to determine the oncogenic and mut...

Journal: :Cancer research 2009
Yedael Y Waldman Tamir Tuller Roded Sharan Eytan Ruppin

The tumor suppressor gene TP53 is known to be a key regulator in cancer, and more than half of human cancers exhibit mutations in this gene. Recent evidence shows that point mutations in TP53 not only disrupt its function but also possess gain-of-function and dominant-negative effects on wild-type copies, thus making the mutated gene an oncogene. Hence, this brings about the possibility that TP...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Laxmi Silwal-Pandit Hans Kristian Moen Vollan Suet-Feung Chin Oscar M Rueda Steven McKinney Tomo Osako David A Quigley Vessela N Kristensen Samuel Aparicio Anne-Lise Børresen-Dale Carlos Caldas Anita Langerød

PURPOSE In breast cancer, the TP53 gene is frequently mutated and the mutations have been associated with poor prognosis. The prognostic impact of the different types of TP53 mutations across the different molecular subtypes is still poorly understood. Here, we characterize the spectrum and prognostic significance of TP53 mutations with respect to the PAM50 subtypes and integrative clusters (IC...

2018
Haruna Furukawa Tomoki Makino Makoto Yamasaki Koji Tanaka Yasuhiro Miyazaki Tsuyoshi Takahashi Yukinori Kurokawa Kiyokazu Nakajima Shuji Takiguchi Masaki Mori Yuichiro Doki

TP53 is associated with the resistance of cytotoxic treatment and patient prognosis, and the mutation rate of TP53 in esophageal squamous cell carcinoma (ESCC) is extraordinarily high, at over 90%. PRIMA-1 (p53 re-activation and induction of massive apoptosis) has recently been reported to restore the function of mutant TP53; however, its antitumor effect and mechanism in ESCC remain unclear. A...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید